首页 | 本学科首页   官方微博 | 高级检索  
     

抗体偶联药物治疗消化系统肿瘤的研究进展
引用本文:程浩,依荷芭丽·迟,石素胜. 抗体偶联药物治疗消化系统肿瘤的研究进展[J]. 现代肿瘤医学, 2022, 0(5): 916-922. DOI: 10.3969/j.issn.1672-4992.2022.05.034
作者姓名:程浩  依荷芭丽·迟  石素胜
作者单位:1.国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院病理科;2.肿瘤内科,北京 100021
摘    要:消化系统肿瘤发病率和病死率较高,对于缺乏手术适应证及放疗、化疗效果不好的患者,亟需发展新型而高效的治疗手段.近年来,抗体-药物偶联物(antibody-drug conjugates,ADC)因其具有抗体药物的高选择性和细胞毒药物的高活性等优点而逐渐成为研究热点,在消化系统肿瘤的治疗中已取得一些成果,但是仍需面对诸多挑...

关 键 词:抗体偶联药物  消化系肿瘤  生物学基础  靶向治疗

The research progress of antibody-drug conjugate therapy in the malignant tumors of digestive system
CHENG Hao,Yihebali·Chi,SHI Susheng. The research progress of antibody-drug conjugate therapy in the malignant tumors of digestive system[J]. Journal of Modern Oncology, 2022, 0(5): 916-922. DOI: 10.3969/j.issn.1672-4992.2022.05.034
Authors:CHENG Hao  Yihebali·Chi  SHI Susheng
Affiliation:1.Department of Pathology;2.Department of Medical Oncology,National Cancer Center/National Clinical Research Center forCancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China.
Abstract:Malignant tumors of digestive system present with relatively high morbidity and mortality.It is urgent to find novel and efficient treatment methods for patients who lack surgical indications or those who with poor radiotherapy and chemotherapy outcomes.Antibody-drug conjugates(ADCs)therapy has gradually become a research hot issue in recent years, with the advantages of both high selectivity of the antibody drug and the activity of cytotoxic drugs.ADCs therapy has made some achievements in the treatment of digestive system neoplasms,but it still needs to face many challenges. Here,we will give a brief review on the recent progress about ADCs in the treatment of tumors of digestive system.
Keywords:antibody-drug conjugate  malignant tumors of digestive system  basic science  targeted therapy
本文献已被 维普 等数据库收录!
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号